(Q35876617)

English

Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer

scientific article published on 23 December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 August 2017

Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer (English)

1 reference

Europe PubMed Central

10 August 2017

author name string

Seok-Mo Kim

1

1 reference

Europe PubMed Central

10 August 2017

Ki-Cheong Park

2

1 reference

Europe PubMed Central

10 August 2017

Jeong-Yong Jeon

3

1 reference

Europe PubMed Central

10 August 2017

Bup-Woo Kim

4

1 reference

Europe PubMed Central

10 August 2017

Hyeung-Kyoo Kim

5

1 reference

Europe PubMed Central

10 August 2017

Ho-Jin Chang

6

1 reference

Europe PubMed Central

10 August 2017

Seung-Hoon Choi

7

1 reference

Europe PubMed Central

10 August 2017

Cheong-Soo Park

8

1 reference

Europe PubMed Central

10 August 2017

Hang-Seok Chang

9

1 reference

Europe PubMed Central

10 August 2017

language of work or name

0 references

publication date

23 December 2015

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

15

1 reference

Europe PubMed Central

10 August 2017

1003

1 reference

Europe PubMed Central

10 August 2017

https://scigraph.springernature.com/pub.10.1186/s12885-015-1982-6

0 references

Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

HDAC Inhibitors as Novel Anti-Cancer Therapeutics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Progress of HDAC inhibitor panobinostat in the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

New and emerging HDAC inhibitors for cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Treatment and prognosis of anaplastic thyroid carcinoma: experience from a single institution in China

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Evidence for a novel anti-apoptotic pathway in human keratinocytes involving the aryl hydrocarbon receptor, E2F1, and checkpoint kinase 1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

HDAC inhibitor-based therapies: can we interpret the code?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

New treatment in advanced thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Targeting class I histone deacetylases in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Histone deacetylases and cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Approach to the patient with anaplastic thyroid carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Epigenetic interplay of histone modifications and DNA methylation mediated by HDA6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

The role of histone deacetylases (HDACs) in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Thyroid carcinoma: molecular pathways and therapeutic targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Chromatin remodeling, cancer and chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Novel histone deacetylase inhibitors in the treatment of thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Epigenomics and epigenetic therapy of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

Histone deacetylases and cancer: causes and therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

11 July 2018

HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

24 September 2018

Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

24 September 2018

Thyroid cancer is the most common cancer associated with acromegaly.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4690331

24 September 2018

American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1982-6

21 January 2018

Anaplastic thyroid cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26698299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radioactive iodine therapy in poorly differentiated thyroid cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26698299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12885-015-1982-6

1 reference

Europe PubMed Central

10 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35876617&oldid=1602640639"